Back to Newsroom

Arbutus Presents HBV Data at 2017 AASLD Liver Meeting

VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 24, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, today presented results from clinical and preclinical studies of HBV therapeutic agents in two oral presentations and five poster presentations, including a late breaker poster presentation, at The Liver Meeting 2017 organized by the American Association for the Study of Liver Diseases (AASLD) held on October 20 – 24, 2017 in Washington, DC. These presentations feature multiple Arbutus pipeline programs that highlight the potential of its product candidates and the breadth of its portfolio being advanced to improve current cure rates in chronic HBV.